MIMESIS : minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissionsoup.com..
DNA-methylation alterations are common in cancer and display unique characteristics that make them ideal markers for tumor quantification and classification. Here we present MIMESIS, a computational framework exploiting minimal DNA-methylation signatures composed by a few dozen informative DNA-methylation sites to quantify and classify tumor signals in tissue and cell-free DNA samples. Extensive analyses of multiple independent and heterogenous datasets including >7200 samples demonstrate the capability of MIMESIS to provide precise estimations of tumor content and to enable accurate classification of tumor type and molecular subtype. To assess our framework for clinical applications, we designed a MIMESIS-informed assay incorporating the minimal signatures for breast cancer. Using both artificial samples and clinical serial cell-free DNA samples from patients with metastatic breast cancer, we show that our approach provides accurate estimations of tumor content, sensitive detection of tumor signal and the ability to capture clinically relevant molecular subtype in patients' circulation. This study provides evidence that our extremely parsimonious approach can be used to develop cost-effective and highly scalable DNA-methylation assays that could support and facilitate the implementation of precision oncology in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Briefings in bioinformatics - 24(2023), 2 vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Romagnoli, Dario [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 27.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/bib/bbad015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35164699X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35164699X | ||
| 003 | DE-627 | ||
| 005 | 20231226051905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bib/bbad015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM35164699X | ||
| 035 | |a (NLM)36653909 | ||
| 035 | |a (PII)bbad015 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Romagnoli, Dario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MIMESIS |b minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 27.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a DNA-methylation alterations are common in cancer and display unique characteristics that make them ideal markers for tumor quantification and classification. Here we present MIMESIS, a computational framework exploiting minimal DNA-methylation signatures composed by a few dozen informative DNA-methylation sites to quantify and classify tumor signals in tissue and cell-free DNA samples. Extensive analyses of multiple independent and heterogenous datasets including >7200 samples demonstrate the capability of MIMESIS to provide precise estimations of tumor content and to enable accurate classification of tumor type and molecular subtype. To assess our framework for clinical applications, we designed a MIMESIS-informed assay incorporating the minimal signatures for breast cancer. Using both artificial samples and clinical serial cell-free DNA samples from patients with metastatic breast cancer, we show that our approach provides accurate estimations of tumor content, sensitive detection of tumor signal and the ability to capture clinically relevant molecular subtype in patients' circulation. This study provides evidence that our extremely parsimonious approach can be used to develop cost-effective and highly scalable DNA-methylation assays that could support and facilitate the implementation of precision oncology in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA-methylation | |
| 650 | 4 | |a bioinformatics | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cell-free DNA | |
| 650 | 4 | |a deconvolution | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a tumor content | |
| 650 | 4 | |a tumor subtype | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a DNA, Neoplasm |2 NLM | |
| 700 | 1 | |a Nardone, Agostina |e verfasserin |4 aut | |
| 700 | 1 | |a Galardi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Paoli, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Biagioni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Gian Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Pestrin, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Sanna, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Moretti, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Demichelis, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Migliaccio, Ilenia |e verfasserin |4 aut | |
| 700 | 1 | |a Biganzoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Malorni, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Benelli, Matteo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Briefings in bioinformatics |d 2000 |g 24(2023), 2 vom: 19. März |w (DE-627)NLM11366883X |x 1477-4054 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:2 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/bib/bbad015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 2 |b 19 |c 03 | ||